Trabectedin

May 17, 2018

PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018

Mar 26, 2018

PharmaMar Announces Participation at the 17th Needham & Co Annual Healthcare Conference in New York City

Feb 20, 2018

PharmaMar's Lurbinectedin ATLANTIS trial design and data in small-cell lung cancer will be an oral presentation at the IASCLC´s annual meeting

Feb 14, 2018

PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

Nov 15, 2017

Phase III Trial With Zepsyre® in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMC

Nov 14, 2017

PharmaMar to Present at the Stifel 2017 Healthcare Conference

Nov 04, 2017

PharmaMar Announces Partnership with 8th National Race to End Women's Cancer in Support of "End Women´s Cancer Weekend" in Washington D.C.

Aug 31, 2017

PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

Jun 20, 2017

FDA Chooses Zepsyre(TM) (PM1183) from PharmaMar to Explore Potential Development for Pediatric Cancers

Jun 16, 2017

PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre(TM)